Greenland Mines Ltd (NASDAQ: GRML) has announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. The company also confirmed that Nasdaq has formally approved its application relating to the March 2026 transaction, resolving prior deficiencies and bringing the company into full compliance with listing requirements.
The strategic pivot is underscored by the completed acquisition of the Sarfartoq project on Sept. 1, following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. The company said planned annual neodymium-praseodymium (NdPr) oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years. This positions Greenland Mines as a significant potential supplier of rare earth magnet materials outside China, a key geopolitical and supply-chain concern.
The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining. This board refresh comes as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project, which are central to its vision of a North Atlantic Critical Metals Corridor linking Greenland resources with allied downstream jurisdictions.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, allows the company to unlock value in its biotech assets while sharpening its focus on mining and critical minerals. This move aligns with growing global demand for rare earth elements essential for electric vehicles, wind turbines, and defense applications, and reduces reliance on Chinese supply chains.
For more information, see the full press release at https://ibn.fm/QN1U9.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: Mining, focused on exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing, the Sarfartoq NdPr rare earths project in southwest Greenland; and Biotech, including Klotho's KLTO-202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
InvestorWire is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. For more information, visit https://www.InvestorWire.com.
